First PCSK9 Inhibitor Approved for Blanket Prevention of Heart Disease

(MedPage Today) — The PCSK9 inhibitor evolocumab (Repatha) got the FDA’s blessing for cardiovascular protection, with or without a history of cardiovascular disease (CVD).
Evolocumab is now indicated for the wider pool of adults at increased…